Physician profile
Mark E Mccabe
NPI 1396107371
$4,509.89
in general payments reported to CMS, 2019-2025
23 companies · $1,093 in 2025
The $1,093 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,002 · 2021: $390 · 2022: $804 · 2023: $958 · 2024: $263 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,279 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,279.23 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $927.86 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $767.37 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $643.60 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Genentech USA, INC. | $286.90 | 2019-2025 | Xolair |
| Grifols USA, LLC | $276.96 | 2021-2025 | Xembify, Gamunex-C |
| Takeda Pharmaceuticals U.S.A., INC. | $262.88 | 2021-2025 | Takhzyro, Cuvitru, Eohilia |
| Glaxosmithkline, LLC. | $245.10 | 2019-2025 | Nucala, Trelegy Ellipta |
| Kaleo, INC. | $192.97 | 2021-2023 | Auvi-Q |
| Biocryst US Sales Co., LLC | $131.63 | 2021-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $124.88 | 2025 | |
| Sanofi-Aventis U.S. LLC | $97.47 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $76.71 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $70.11 | 2023-2025 | Ryaltris |
| Pfizer INC. | $66.19 | 2021-2025 | |
| Pharming Healthcare, INC. | $65.71 | 2022-2025 | Ruconest |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.14 | 2021-2022 | |
| Csl Behring | $42.33 | 2022-2023 | Hizentra |
| Kowa Pharmaceuticals America, INC. | $38.70 | 2025 | Zoryve |
| Amgen INC. | $34.00 | 2025 | |
| Ionis Pharmaceuticals, INC. | $33.05 | 2025 | Dawnzera |
| Incyte Corporation | $26.33 | 2022 | |
| Merck Sharp & Dohme LLC | $18.92 | 2021 | |
| Arcutis Biotherapeutics, INC. | $16.08 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mccabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.